Articles

Patients who were non–transplant eligible, newly diagnosed with multiple myeloma (NDMM) and frail have inferior overall survival (OS), primarily because of treatment discontinuation due to toxicity. Therefore, evaluation of less-toxic effective therapies, such as the oral proteasome inhibitor ixazomib (Ixa) and the monoclonal anti-CD38 antibody daratumumab (Dara), is critical for this patient population as well as the elderly. Read More ›

The CANDOR trial was a randomized, open-label, phase 3 study in which carfilzomib, dexamethasone, and daratumumab were compared with carfilzomib and dexamethasone (Kd) for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who had undergone 1 to 3 prior lines of therapy. Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM), although promising efficacy and acceptable toxicity were reported for belantamab mafodotin plus pomalidomide and dexamethasone, the high dose rate holds at the 2.5-mg/kg dose level were deemed to warrant examination of alternative-dosing schedules. Read More ›

Because multiple myeloma is a progressive disease and requires continued successive therapies, and there are few treatment options for patients who are refractory to anti-CD38 monoclonal antibodies, new therapies are needed. Read More ›

Results from a phase 3 study of a circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) combined with thalidomide and dexamethasone showed this was a safe and effective treatment for patients with relapsed/refractory multiple myeloma (RRMM), including those with a poor prognosis. Read More ›

The GMMG-HD6 study, an ongoing phase 3, randomized, open-label, multicenter trial, examines the effect of bortezomib, lenalidomide, and dexamethasone (VRD) with or without the addition of elotuzumab as induction therapy for newly diagnosed transplant-eligible patients with multiple myeloma (MM). Read More ›

Patients with light chain (AL) amyloidosis who were previously treated found encouraging efficacy and a good safety profile based on preliminary results from a phase 2 study of isatuximab. Read More ›

According to the IKEMA study interim analysis, isatuximab (Isa) plus carfilzomib and dexamethasone (Isa-Kd) resulted in a clinically meaningful improvement in depth of response; more patients reached minimal residual disease (MRD)-negative status when compared with those patients who received carfilzomib and dexamethasone alone. Read More ›

IKEMA is an ongoing, phase 3, randomized, open-label, parallel-group study that reached its interim analysis milestone. The study evaluated the effect of adding isatuximab (Isa) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

The ongoing GMMG-Concept trial is a phase 2, multicenter, investigator-initiated, open-label trial examining the induction, consolidation, and maintenance treatment of the 4-drug combination of isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients newly diagnosed with high-risk multiple myeloma (MM); this includes both transplant-eligible and non–transplant-eligible patients. Read More ›